OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantBB
British Business Bank
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Sep 18, 2026
British Business Bank is the UK’s economic development bank, supporting business access to finance through investment programmes, funds and financing partners.
Its Future Fund: Breakthrough programme, delivered by British Patient Capital, co-invests with private investors in later-stage, R&D-intensive UK companies. It targets technologies such as quantum computing, cleantech and life sciences, where development requires substantial capital.
Applications to that programme come from a qualifying sponsor investor, rather than directly from the company. The published criteria require a round of at least £30 million, with the programme contributing no more than 30% on the sponsor investor’s terms.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $438.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionSalience Labs
Salience Labs develops silicon photonic switches for datacenter operators connecting large AI computing clusters.
$125MSeries B
ParticipantCSignum
CSignum makes wireless communications technology that lets IoT sensors transmit data from underwater and underground infrastructure without conventional cable runs.
£2.6MFollow-on funding
Participant